Oxidative stress and mitochondrial dysfunction have been linked to dopaminergic neuron degeneration in Parkinson disease. We have previously shown that dopamine oxidation leads to selective dopaminergic terminal degeneration in vivo and alters mitochondrial function in vitro. In this study, we utilized 2-D difference in-gel electrophoresis to assess changes in the mitochondrial proteome following in vitro exposure to reactive dopamine quinone. A subset of proteins exhibit decreased fluorescence labeling following dopamine oxidation, suggesting a rapid loss of specific proteins. Amongst these proteins are mitochondrial creatine kinase, mitofilin, mortalin, the 75 kDa subunit of NADH dehydrogenase, and superoxide dismutase 2. Western blot analyses for mitochondrial creatine kinase and mitofilin confirmed significant losses in isolated brain mitochondria exposed to dopamine quinone and PC12 cells exposed to dopamine. These results suggest that specific mitochondrial proteins are uniquely susceptible to changes in abundance following dopamine oxidation, and carry implications for mitochondrial stability in Parkinson disease neurodegeneration.
Introduction
Parkinson disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra (SN) pars compacta and the formation of Lewy bodies (Samii et al., 2004) . Most PD cases are considered sporadic, and provide us with limited clues to causes of disease pathogenesis. However, increasing evidence implicates mitochondrial dysfunction and oxidative stress in PD (Betarbet et al., 2002; Dauer and Przedborski, 2003; Jenner, 2003; Pallanck and Greenamyre, 2006) .
Decreased mitochondrial Complex I (NADH dehydrogenase) activity has been observed in both the SN (Janetzky et al., 1994; Orth and Schapira, 2002; Schapira et al., 1990) and periphery (Blandini et al., 1998; Shoffner et al., 1991) of PD patients. Deficiencies and inhibition of the mitochondrial electron transport chain (ETC), a known source of reactive oxygen species (ROS), can lead to increased mitochondria-generated free radicals and oxidative stress (Beal, 2003; Lenaz et al., 2002) . Increased ROS may cause damage to macromolecules, such as increased oxidation of mitochondrial proteins, making them susceptible to accumulation or proteolytic degradation (Bota and Davies, 2001, 2002; Bulteau et al., 2006) .
Although multiple brain regions are involved in PD, the degeneration of dopaminergic neurons under conditions of oxidative stress suggests dopamine (DA) may be contributing to PD pathogenesis (Greenamyre and Hastings, 2004; Ogawa et al., 2005; Stokes et al., 1999) . Normal DA metabolism leads to the production of ROS, and DA not adequately stored in vesicles is prone to oxidation, forming the reactive DA quinone (DAQ) (Graham et al., 1978) . Dopamineinduced toxicity, demonstrated both in cell culture (Jones et al., 2000; Koshimura et al., 2000) and in vivo (Hastings et al., 1996; Rabinovic et al., 2000) , is dependent on DA oxidation and the formation of reactive DA metabolites. Post-mortem studies have found increased levels of cysteinyl-DA, the covalent modification of cysteine by DAQ, in SN of PD patients (Fornstedt et al., 1989; Spencer et al., 1998) . Dopamine and DAQ exposure also alter mitochondrial respiration (Berman and Hastings, 1999; Cohen et al., 1997; Gluck et al., 2002) and trigger permeability transition (Berman and Hastings, 1999) in isolated rat brain mitochondria, suggesting modification of critical mitochondrial proteins, though specific proteins have yet to be identified. As previous proteomic studies have identified alterations in mitochondrial proteins in animal models of PD (Jin et al., 2005; Palacino et al., 2004 
